GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Meribank Biotech Co Ltd (ROCO:4724) » Definitions » EV-to-EBITDA

Meribank Biotech Co (ROCO:4724) EV-to-EBITDA : -24.65 (As of Jun. 05, 2024)


View and export this data going back to 2023. Start your Free Trial

What is Meribank Biotech Co EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Meribank Biotech Co's enterprise value is NT$2,282.0 Mil. Meribank Biotech Co's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was NT$-92.6 Mil. Therefore, Meribank Biotech Co's EV-to-EBITDA for today is -24.65.

The historical rank and industry rank for Meribank Biotech Co's EV-to-EBITDA or its related term are showing as below:

ROCO:4724' s EV-to-EBITDA Range Over the Past 10 Years
Min: -41.54   Med: -31.64   Max: -18.19
Current: -24.65

During the past 6 years, the highest EV-to-EBITDA of Meribank Biotech Co was -18.19. The lowest was -41.54. And the median was -31.64.

ROCO:4724's EV-to-EBITDA is ranked worse than
100% of 451 companies
in the Biotechnology industry
Industry Median: 9.15 vs ROCO:4724: -24.65

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-06-05), Meribank Biotech Co's stock price is NT$37.30. Meribank Biotech Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was NT$-1.990. Therefore, Meribank Biotech Co's PE Ratio for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


Meribank Biotech Co EV-to-EBITDA Historical Data

The historical data trend for Meribank Biotech Co's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Meribank Biotech Co EV-to-EBITDA Chart

Meribank Biotech Co Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBITDA
Get a 7-Day Free Trial - - - - -24.95

Meribank Biotech Co Semi-Annual Data
Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -24.95

Competitive Comparison of Meribank Biotech Co's EV-to-EBITDA

For the Biotechnology subindustry, Meribank Biotech Co's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Meribank Biotech Co's EV-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Meribank Biotech Co's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Meribank Biotech Co's EV-to-EBITDA falls into.



Meribank Biotech Co EV-to-EBITDA Calculation

Meribank Biotech Co's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=2282.001/-92.563
=-24.65

Meribank Biotech Co's current Enterprise Value is NT$2,282.0 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Meribank Biotech Co's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was NT$-92.6 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Meribank Biotech Co  (ROCO:4724) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Meribank Biotech Co's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=37.30/-1.990
=At Loss

Meribank Biotech Co's share price for today is NT$37.30.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Meribank Biotech Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was NT$-1.990.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Meribank Biotech Co EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Meribank Biotech Co's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Meribank Biotech Co (ROCO:4724) Business Description

Traded in Other Exchanges
N/A
Address
Sector 1, Neihu Road, 1st Floor, No.68, Neihu District, Taipei, TWN, 11493
Meribank Biotech Co Ltd is engaged in Research and development and sales of new cell drugs and also Umbilical cord blood, placenta and umbilical cord mesenchymal stem cells processing, testing and cryopreservation.

Meribank Biotech Co (ROCO:4724) Headlines

No Headlines